St. Jude Medical estimates raised by 5% at UBS UBS raised St. Jude estimates by 5% following the company's new $1B repurchase plan. The firm believes the repurchase is 2-3x greater than investors were expecting and is a major vote of confidence by the board. Shares are Buy rated with a $44 price target.
St. Jude Medical weakness a buying opportunity, says CRT Capital CRT Capital would use St. Jude Medical weakness as a buying opportunity based on accelerating EPS growth and expects CardioMEMS to be a $1B revenue opportunity over the next few years. Shares are Buy rated with a $80 price target.